Prostate Cancer updates: Test identifies aggressive disease, diet affects progression risk
Click Here to Manage Email Alerts
National Prostate Cancer Awareness Month is observed every September.
An estimated 299,010 men in the United States will be diagnosed with prostate cancer this year and about 35,250 men will die of the disease, according to American Cancer Society.
National Prostate Cancer Awareness Month is intended to educate men about prostate cancer risk factors, screening and treatment options.
In conjunction with the observance, Healio presents the following updates in prostate cancer research that may be relevant to your practice.
1. Olaparib (Lynparza; AstraZeneca, Merck) monotherapy may be an effective treatment option for certain men with biochemically recurrent prostate cancer, according to results of a nonrandomized phase 2 trial. Read more.
2. The addition of a pre-ketone supplement to an immunotherapy regimen demonstrated efficacy for treating prostate cancer. Read more.
3. Men with bone pain at diagnosis of metastatic hormone-resistant prostate cancer had shorter survival than men without bone pain. Read more.
4. Active surveillance for men with favorable-risk prostate cancer is an effective management strategy, according to data from a prospective cohort study. Read more.
5. Men with nonmetastatic prostate cancer who ate more plant-based foods experienced significantly lower risk for disease progression than individuals who ate lower quantities. Read more.
6. Tumor mutational burden may help predict benefit of immune checkpoint inhibitor therapy for men with metastatic castration-resistant prostate cancer. Read more.
7. A urine-based test for men with prostate cancer can distinguish the slow-growing form of the disease from the more aggressive type that would require immediate treatment. Read more.
8. The American Urological Association released a clinical practice guideline pertaining to salvage therapy for men with prostate cancer. The guideline includes 30 recommendations for treating men with localized disease who underwent definitive local therapy and experienced PSA recurrence. Read more.
9. Adverse events experienced by men with prostate cancer varied considerably based on the treatment they received, results of a 10-year follow-up study showed. Read more.
10. A 10-minute video designed to educate Black men on prostate cancer risks prompted 93% of viewers to report they intend to be screened in the future. Read more.
11. Transgender women are significantly less likely than cisgender men to undergo prostate cancer screening. The principal driver of the disparity appears to be whether physicians recommended testing — not access to care. Read more.
Reference:
- American Cancer Society. Key statistics for prostate cancer. Available at: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html. Accessed Sept. 10, 2024.
Collapse
Healio Coverage
Click Here to Manage Email Alerts